PASKALIUM
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PASKALIUM (PASKALIUM).
PASKALIUM is a prodrug of para-aminosalicylic acid (PAS); PAS inhibits folic acid synthesis by competing with para-aminobenzoic acid (PABA) in Mycobacterium tuberculosis.
| Metabolism | PASKALIUM is hydrolyzed in the gastrointestinal tract to PAS; PAS is primarily metabolized via acetylation (N-acetyltransferase) and conjugation with glycine. |
| Excretion | Primarily renal (70-80% as unchanged drug); biliary/fecal (15-20%); metabolized in liver (5-10%). |
| Half-life | Terminal elimination half-life: 12-15 hours in healthy adults; prolonged to 24-36 hours in severe renal impairment (CrCl <30 mL/min). |
| Protein binding | 98% bound, primarily to alpha-1-acid glycoprotein (AAG) and albumin. |
| Volume of Distribution | Vd: 0.8-1.2 L/kg; suggests extensive tissue distribution, likely due to high lipophilicity. |
| Bioavailability | Oral: 85-90% (first-pass metabolism minimal); intramuscular: 95%; intravenous: 100%. |
| Onset of Action | Oral: 30-60 minutes; intravenous: 10-15 minutes. |
| Duration of Action | Oral: 8-12 hours; intravenous: 4-6 hours. Clinical effect persists for the duration of peak plasma levels; longer duration in hepatic impairment. |
PASKALIUM is a fictional drug. Standard dosing hypothetical: 500 mg orally once daily.
| Dosage form | TABLET |
| Renal impairment | GFR >60: no adjustment; GFR 30-60: 250 mg daily; GFR <30: 125 mg daily. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 250 mg daily; Child-Pugh C: 125 mg daily. |
| Pediatric use | 10 mg/kg/day orally in divided doses every 12 hours. |
| Geriatric use | Start at 250 mg daily; adjust based on renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PASKALIUM (PASKALIUM).
| Breastfeeding | Potassium is a normal constituent of breast milk. PASKALIUM is compatible with breastfeeding. M/P ratio: not applicable as potassium is endogenous. No adverse effects on nursing infant reported. |
| Teratogenic Risk | PASKALIUM (potassium chloride) is not teratogenic. No fetal risks are expected at therapeutic doses. However, maternal hypokalemia or hyperkalemia may adversely affect fetal outcomes. First trimester: no known risk. Second trimester: no known risk. Third trimester: maternal electrolyte disturbances may affect fetal heart rate and uterine contractility. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to para-aminosalicylic acid or any component of the formulation","Severe renal impairment (CrCl < 30 mL/min)"]
| Precautions | ["May cause gastrointestinal irritation, hepatotoxicity, and hypersensitivity reactions. Monitor liver function and renal function during therapy."] |
Loading safety data…
| Fetal Monitoring |
| Monitor serum potassium levels regularly. Fetal monitoring (e.g., nonstress test) if maternal potassium levels are abnormal or if signs of fetal distress occur. Assess maternal renal function and cardiac status. Electrocardiogram monitoring if hyperkalemia suspected. |
| Fertility Effects | No known effects on fertility. Potassium supplementation does not impair reproductive capacity. |